Lexeo Therapeutics (LXEO) Operating Income: 2022-2023
Historic Operating Income for Lexeo Therapeutics (LXEO) over the last 1 years, with Dec 2023 value amounting to -$15.0 million.
- Lexeo Therapeutics' Operating Income rose 1.47% to -$15.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$68.5 million, marking a year-over-year change of. This contributed to the annual value of -$105.8 million for FY2024, which is 54.37% down from last year.
- According to the latest figures from Q4 2023, Lexeo Therapeutics' Operating Income is -$15.0 million, which was up 26.14% from -$20.3 million recorded in Q3 2023.
- Lexeo Therapeutics' 5-year Operating Income high stood at -$14.0 million for Q2 2023, and its period low was -$20.3 million during Q3 2023.
- In the last 2 years, Lexeo Therapeutics' Operating Income had a median value of -$16.3 million in 2022 and averaged -$16.9 million.
- The largest annual percentage gain for Lexeo Therapeutics' Operating Income in the last 5 years was 1.47% (2023), contrasted with its biggest fall of 15.96% (2023).
- Over the past 2 years, Lexeo Therapeutics' Operating Income (Quarterly) stood at -$15.2 million in 2022, then rose by 1.47% to -$15.0 million in 2023.
- Its Operating Income stands at -$15.0 million for Q4 2023, versus -$20.3 million for Q3 2023 and -$14.0 million for Q2 2023.